CA3216090A1 - Compounds for use in the treatment of hyperproliferative disorders - Google Patents

Compounds for use in the treatment of hyperproliferative disorders Download PDF

Info

Publication number
CA3216090A1
CA3216090A1 CA3216090A CA3216090A CA3216090A1 CA 3216090 A1 CA3216090 A1 CA 3216090A1 CA 3216090 A CA3216090 A CA 3216090A CA 3216090 A CA3216090 A CA 3216090A CA 3216090 A1 CA3216090 A1 CA 3216090A1
Authority
CA
Canada
Prior art keywords
alkyl
thiazol
indo1
methyl
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3216090A
Other languages
English (en)
French (fr)
Inventor
Hector Garcia Palmer
Isabel PUIG BORREIL
Josep TABERNERO CATURLA
Carlos GALDEANO CANTADOR
Diego Munoz-Torrero Lopez-Ibarra
Xavier BARRIL ALONSO
Sergio RUIZ CARMONA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat de Barcelona UB
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Original Assignee
Universitat de Barcelona UB
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat de Barcelona UB, Institucio Catalana de Recerca i Estudis Avancats ICREA, Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron filed Critical Universitat de Barcelona UB
Publication of CA3216090A1 publication Critical patent/CA3216090A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3216090A 2021-04-21 2022-04-21 Compounds for use in the treatment of hyperproliferative disorders Pending CA3216090A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382343.8 2021-04-21
EP21382343.8A EP4079304A1 (en) 2021-04-21 2021-04-21 Compounds for use in the treatment of hyperproliferative disorders
PCT/EP2022/060579 WO2022223704A1 (en) 2021-04-21 2022-04-21 Compounds for use in the treatment of hyperproliferative disorders

Publications (1)

Publication Number Publication Date
CA3216090A1 true CA3216090A1 (en) 2022-10-27

Family

ID=75674747

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3216090A Pending CA3216090A1 (en) 2021-04-21 2022-04-21 Compounds for use in the treatment of hyperproliferative disorders

Country Status (11)

Country Link
US (1) US20240208998A1 (enExample)
EP (2) EP4079304A1 (enExample)
JP (1) JP2024515705A (enExample)
KR (1) KR20240013112A (enExample)
CN (1) CN117320715A (enExample)
AU (1) AU2022260529A1 (enExample)
BR (1) BR112023021959A2 (enExample)
CA (1) CA3216090A1 (enExample)
IL (1) IL307868A (enExample)
MX (1) MX2023012457A (enExample)
WO (1) WO2022223704A1 (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2609912T3 (es) * 2007-06-22 2017-04-25 Hydra Biosciences, Inc. Compuestos de 2,6-dioxo, -2,3-dihidro-1h-purina útiles para el tratamiento de trastornos relacionados con la actividad del canal trpa1

Also Published As

Publication number Publication date
JP2024515705A (ja) 2024-04-10
WO2022223704A1 (en) 2022-10-27
IL307868A (en) 2023-12-01
MX2023012457A (es) 2023-11-22
EP4079304A1 (en) 2022-10-26
KR20240013112A (ko) 2024-01-30
AU2022260529A1 (en) 2023-11-09
US20240208998A1 (en) 2024-06-27
BR112023021959A2 (pt) 2023-12-26
CN117320715A (zh) 2023-12-29
EP4326262A1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
EP3694853B1 (en) Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
CN102816175B (zh) 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
KR20230142710A (ko) 캄프토테신 화합물, 그의 제조방법 및 그의 응용
US6919351B2 (en) Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
US20040044207A1 (en) Aza-and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
CN117940432A (zh) 一种喜树碱类化合物、其制备方法和用途
KR20200096265A (ko) Prmt5 억제제로서의 헤테로시클릭 화합물
KR20180086221A (ko) Ror-감마의 조절물질
Ning et al. Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2
CA2425067A1 (en) Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
CN101448840A (zh) 四氢吡啶并噻吩并嘧啶化合物及其使用方法
CN115448921B (zh) 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
Ma et al. Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological evaluation
CA3147407A1 (en) Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
WO2019034178A1 (zh) 一种dna毒性二聚体化合物
CA3216090A1 (en) Compounds for use in the treatment of hyperproliferative disorders
WO2007022241A2 (en) Novel high affinity quinoline-based kinase ligands
CN119053607B (zh) 喜树碱类化合物及其偶联物、其制备方法和用途
EA048831B1 (ru) Соединения для применения при лечении гиперпролиферативных заболеваний
Dassonneville et al. Rhodium Catalyzed [2π+ 2π+ 2π]-Cycloaddition of Alkynyl-Ynamides and Carbon Disulfide to Indolo-Thiopyrane Thiones
JP2022534998A (ja) Ｐｒｍｔ５阻害剤としての複素環式化合物
Zhang et al. Synthesis and biological evaluation of novel 1, 2, 3-benzotriazin-4-one derivatives as leukotriene A4 hydrolase aminopeptidase inhibitors
WO2006081659A1 (en) Meroterpenoid inhibitors of phosphoinositide 3 kinase (pi3k)
WO2021206955A1 (en) Macrocyclic compounds as kinases inhibitors and uses thereof
CN113387879A (zh) 一种胺类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250411

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250411

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260310

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260310

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260325

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260325

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260331

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260331

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260331